{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Synovial+Sarcomas", "query": { "condition": "Synovial Sarcomas" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 92, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Synovial+Sarcomas&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T05:55:52.121Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03520959", "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Synovial Sarcoma", "Cancer", "Soft Tissue Sarcoma", "Sarcoma", "Metastatic Sarcoma" ], "interventions": [ { "name": "LV305", "type": "BIOLOGICAL" }, { "name": "G305", "type": "BIOLOGICAL" }, { "name": "LV305-matching placebo", "type": "OTHER" }, { "name": "G305-matching placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1, "start_date": "2018-09-18", "completion_date": "2018-11-20", "has_results": true, "last_update_posted_date": "2020-04-16", "last_synced_at": "2026-07-23T05:55:52.121Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 24 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03520959" }, { "nct_id": "NCT02650986", "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Fallopian Tube Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Carcinoma", "Advanced Primary Peritoneal Carcinoma", "Advanced Synovial Sarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Fallopian Tube Carcinoma", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Metastatic Synovial Sarcoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IIIA Fallopian Tube Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Primary Peritoneal Cancer AJCC v8", "Stage IIIA1 Fallopian Tube Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Fallopian Tube Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Fallopian Tube Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Primary Peritoneal Cancer AJCC v8", "Stage IIIC Fallopian Tube Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8", "Unresectable Melanoma", "Unresectable Ovarian Carcinoma", "Unresectable Synovial Sarcoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2017-07-14", "completion_date": "2032-07-14", "has_results": true, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-23T05:55:52.121Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650986" }, { "nct_id": "NCT06625190", "title": "Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma", "Rhabdomyosarcoma", "Synovial Sarcoma", "Peripheral Nerve Sheath Tumors", "Clear Cell Sarcoma", "Alveolar Soft Part Sarcoma", "Desmoplastic Small Round Cell Tumor", "Chordoma", "Rhabdoid Tumor", "Epithelioid Sarcoma", "Myoepithelial Tumor", "Osteosarcoma", "Ewing Sarcoma", "Wilms Tumor" ], "interventions": [ { "name": "Miltenyi CliniMACS Prodigy ® system", "type": "DEVICE" }, { "name": "Zoledronic acid", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "6 Months to 25 Years" }, "enrollment_count": 27, "start_date": "2026-02-11", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-07-23T05:55:52.121Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625190" }, { "nct_id": "NCT00949325", "title": "Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "temsirolimus plus liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 24, "start_date": "2009-09", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2019-03-11", "last_synced_at": "2026-07-23T05:55:52.121Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949325" }, { "nct_id": "NCT00003718", "title": "Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Ovarian Cancer", "Sarcoma" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Herbert Irving Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "1998-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-07-23T05:55:52.121Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003718" }, { "nct_id": "NCT05227326", "title": "AOH1996 for the Treatment of Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Malignant Solid Neoplasm", "Osteosarcoma", "Leiomyosarcomas", "Synovial Sarcomas", "Ovarian Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "PCNA Inhibitor AOH1996", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2022-08-12", "completion_date": "2029-09-13", "has_results": false, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-07-23T05:55:52.121Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Duarte, California", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05227326" }, { "nct_id": "NCT00027911", "title": "Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "NY-ESO-1 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-04", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-07-23T05:55:52.121Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027911" }, { "nct_id": "NCT04028479", "title": "The Registry of Oncology Outcomes Associated With Testing and Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma", "Adenocystic Carcinoma", "Anal Cancer", "Appendix Cancer", "Brain Tumor", "Glioblastoma", "Astrocytoma", "Bile Duct Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Bone Cancer", "Synovial Sarcoma", "Chondrosarcoma", "Liposarcoma", "Sarcoma, Kaposi", "Sarcoma,Soft Tissue", "Sarcoma", "Osteosarcoma", "CNS Cancer", "Brain Stem Neoplasms", "Breast Cancer", "Cervical Cancer", "Colorectal Cancer", "Rectal Cancer", "Colon Cancer", "Esophageal Cancer", "Esophagus Cancer", "Cancer of Colon", "Pancreatic Cancer", "Cancer of Pancreas", "Testis Cancer", "Testicular Cancer", "Ureter Cancer", "Renal Cell Carcinoma", "Kidney Cancer", "Gestational Trophoblastic Tumor", "Head and Neck Neoplasms", "Parotid Tumor", "Larynx Cancer", "Tongue Cancer", "Pharynx Cancer", "Salivary Gland Cancer", "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Multiple Myeloma", "Non Hodgkin Lymphoma", "Carcinoid Tumor", "Lung Cancer", "Neuroendocrine Tumors", "Mesothelioma", "Thyroid Cancer", "Parathyroid Neoplasms", "Adrenal Cancer", "Small Bowel Cancer", "Stomach Cancer", "Liver Cancer", "Hepatic Cancer", "Melanoma", "Skin Cancer", "Unknown Primary Tumors", "Uterine Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Prostate Cancer", "Vaginal Cancer", "Penile Cancer", "Vulvar Cancer", "Waldenstrom Macroglobulinemia", "Cancer, Advanced", "Thymus Cancer", "Nasopharyngeal Carcinoma", "Multiple Endocrine Neoplasia", "Pheochromocytoma", "Small Cell Carcinoma", "Pulmonary Carcinoma" ], "interventions": [ { "name": "Biomarker Testing (L)", "type": "DIAGNOSTIC_TEST" }, { "name": "Systemic Treatment (T)", "type": "DRUG" }, { "name": "Patient Reported Outcomes (P)", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG", "OTHER" ], "sponsor": "Taproot Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2021-05-05", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-07-23T05:55:52.121Z", "location_count": 2, "location_summary": "Idaho Falls, Idaho • Laredo, Texas", "locations": [ { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Laredo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028479" }, { "nct_id": "NCT04420975", "title": "Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leiomyosarcoma", "Malignant Peripheral Nerve Sheath Tumor", "Myxofibrosarcoma", "Pleomorphic Rhabdomyosarcoma", "Resectable Dedifferentiated Liposarcoma", "Resectable Soft Tissue Sarcoma", "Resectable Undifferentiated Pleomorphic Sarcoma", "Soft Tissue Fibrosarcoma", "Spindle Cell Sarcoma", "Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8", "Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IA Retroperitoneal Sarcoma AJCC v8", "Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IB Retroperitoneal Sarcoma AJCC v8", "Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage II Retroperitoneal Sarcoma AJCC v8", "Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage III Retroperitoneal Sarcoma AJCC v8", "Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IIIA Retroperitoneal Sarcoma AJCC v8", "Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IIIB Retroperitoneal Sarcoma AJCC v8", "Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Storiform-Pleomorphic Malignant Fibrous Histiocytoma", "Synovial Sarcoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone", "Undifferentiated Pleomorphic Sarcoma", "Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells", "Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant", "Undifferentiated Spindle Cell Sarcoma" ], "interventions": [ { "name": "Definitive Surgical Resection", "type": "PROCEDURE" }, { "name": "Nanoplexed Poly I:C BO-112", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-10-14", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-07-23T05:55:52.121Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04420975" }, { "nct_id": "NCT03670069", "title": "Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Leiomyosarcoma", "Metastatic Synovial Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Advanced Myxoid Liposarcoma", "Advanced Soft Tissue Sarcoma", "Metastatic Myxoid Liposarcoma", "Metastatic Round Cell Liposarcoma", "Metastatic Soft Tissue Sarcoma", "Refractory Leiomyosarcoma", "Refractory Myxoid Liposarcoma", "Refractory Round Cell Liposarcoma", "Refractory Soft Tissue Sarcoma", "Refractory Synovial Sarcoma", "Refractory Undifferentiated Pleomorphic Sarcoma", "Advanced Leiomyosarcoma", "Advanced Synovial Sarcoma", "Advanced Undifferentiated Pleomorphic Sarcoma", "Metastatic Chondrosarcoma" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2019-09-30", "completion_date": "2024-05-06", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-07-23T05:55:52.121Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03670069" } ] }